Note: Descriptions are shown in the official language in which they were submitted.
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 1 -
CHELATED NANOCERIA FOR THE TREATMENT OF
OXIDATIVE STRESS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This patent application claims priority to Provisional Application
Ser. No.
61/854,507, STABILIZED NANOCERIA FOR THE TREATMENT OF OXIDATIVE
STRESS, filed April 25, 2013, the disclosure of which is incorporated herein
by reference in
its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates in general to improvements in the
field of nano-
medicine. In particular, the invention relates to cerium-containing
nanoparticles prepared
with biocompatible materials, to methods of preparing such nanoparticles, and
to the-use of
such nanoparticles to treat disease, such as a neurodegenerative disease, or
to treat
complications due to oxidative stress arising from, for example, ischemic
stroke.
BACKGROUND OF THE INVENTION
[0003] Oxidative stress plays a major role in the pathogenesis of many
human diseases,
and in particular, neurodegenerative diseases. Treatment with antioxidants,
which may
reduce particular free radical species, therefore, might theoretically prevent
tissue damage
and improve both survival and neurological outcome. Free radicals in
physiological
environments can often be classified as either a reactive oxygen species (ROS)
or a reactive
nitrogen species (RNS). Free radicals are highly reactive chemical species and
readily react
with proteins, lipids and nucleic acids at a subeellular level and thereby
contribute to the
progression of various diseases and events producing oxidative stress, such as
ischemic
stroke.
[0004] The origin of the use of nanoceria in nano-medicine can be traced
to the seminal
work of Bailey and Rzigalinski, wherein the application of ultrafine cerium
oxide particles
to brain cells in culture was observed to greatly enhanced cell survivability,
as described by
Rzigalinski in Nanoparticles and Cell Longevity, Technology in Cancer Research
&
Treatment 4(6), 651-659 (2005). More particularly, rat brain cell cultures in
vitro were
shown to survive approximately 3-4 times longer when treated with 2-10
nanometer (nm)
sized cerium oxide nanoparticles synthesized by a reverse micelle micro
emulsion
technique, as disclosed by Rzigalinski et al. in U.S. Patent 7,534,453, filed
Sept. 4, 2003.
Cultured brain cells exposed to a lethal dose of free radicals generated by
hydrogen
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 2 -
peroxide or ultraviolet light exposures were afforded considerable protection
by the cerium
oxide nanoparticles. In addition, the cerium oxide nanoparticles were reported
to be
relatively inert in the murine body, with low toxicity (e.g. tail vein
injections produced no
toxic effects). While no in vivo medical benefits were reported, benefits were
postulated for
treatments with these ceria nanoparticles, including reduced inflammation
associated with
wounds, implants, arthritis, joint disease, vascular disease, tissue aging,
stroke and traumatic
brain injury.
[0005] However, a host of problems with these particular nanoceria
particles was
subsequently disclosed by Rzigalinski et al. in WO 2007/002662. Nanoceria
produced by
this reverse micelle micro emulsion technique suffered from several problems:
(1) particle
size was not well-controlled within the reported 2-10 nanometer (nm) range,
making
variability between batches high; (2) tailing of surfactants, such as sodium
bis(ethylhexyl)sulphosuccinate, also known as docusate sodium or (AOT), used
in the
process into the final product caused toxic responses; (3) inability to
control the amount of
surfactant tailing posed problems with agglomeration when these nanoparticles
were placed
in biological media, resulting in reduced efficacy and deliverability; and (4)
instability of
the valence state of cerium (+3/+4) over time. Thus, the cerium oxide
nanoparticles
produced by the reverse micelle micro emulsion technique were highly variable
from batch
to batch, and showed higher than desired toxicity to mammalian cells.
[0006] As an alternative, Rzigalinski et al. in WO 2007/002662 describe the
biological
efficacy of nanoceria synthesized by high temperature techniques, obtained
from at least
three commercial sources. These new sources of cerium oxide nanoparticles were
reported
to provide superior reproducibility of activity from batch to batch. It was
further reported
that, regardless of source, cerium oxide particles having a small size, narrow
size
distribution, and low agglomeration rate are most advantageous. In regard to
size, this
disclosure specifically teaches that in embodiments where particles are taken
into the
interior of cells, the preferable size range of particles that are taken into
the cell are from
about 11 nm to about 50 nm, such as about 20 nm. In embodiments where
particles exert
their effects on cells from outside the cells, the preferable size range of
these extracellular
particles is from about 11 nm to about 500 nm.
[0007] These inventors (Rzigalinski et al.) also report that for
delivery, the nanoparticles
were advantageously in a non-agglomerated form. To accomplish this, they
reported that
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 3 -
stock solutions of about 10% by weight could be sonicated in ultra-high purity
water or in
normal saline prepared with ultra-high purity water. However, as others have
noted, we
have observed that sonicated aqueous dispersions of nanoceria synthesized by
high
temperature techniques (e.g. obtained from commercial sources) are highly
unstable, and
settle rapidly (i.e. within minutes), causing substantial variability in
administering aqueous
dispersions of nanoceria derived from these sources.
[0008] Hardas et al., Toxicological Sciences 116(2), 562-576 (2010),
report on the
biodistribution and toxicology effects of aqueous dispersions of nanoceria
prepared by the
direct two-step hydrothermal preparation of Masui et al., Mater. Sci. Lett.
21, 489-491
(2002), in which sodium citrate is included as a biocompatible stabilizer.
High resolution
TEM revealed that this form of nanoceria possessed crystalline polyhedral
particle
morphology with sharp edges and a narrow size distribution of 4-6 nm. These
citrate
stabilized ceria nanoparticle dispersions were reported to be stable for more
than 2 months
at a physiological pH of 7.35. Thus, no sonication prior to administration was
required.
[0009] Quite surprisingly, however, they report that compared with
previously studied
commercially sourced nanoceria (Aldrich Chemical Co. (Cat. #639648)), this
form of
citrate stabilized nanoceria was more toxic, was not seen in the brain, and
produced little
oxidative stress effect to the hippocampus and cerebellum.
[0010] DiFrancesco et al. in commonly assigned PCT/US2007/077545, METHOD
OF
PREPARING CERIUM DIOXIDE NANOPARTICLES, filed September, 4, 2007, describes
the oxidation of cerous ion by hydrogen peroxide at low pH (<4.5) in the
presence of
biocompatible stabilizers, such as citric acid (CA), lactic acid, tartaric
acid, gluconic acid,
ethylenediaminetetraacetic acid (EDTA), and combinations thereof.
Specifically, the
stabilizer lactic acid and the combination of lactic acid and EDTA are shown
to directly
produce stable dispersions of nanoceria of average particle size in the range
of 3-8 nm.
[0011] Reed et al. in commonly assigned US2013/0337083, NANOCERIA FOR THE
TREATMENT OF OXIDATIVE STRESS, filed March 15, 2013, describes a synergistic
increase in hippocampal cell sparing for mice treated with nanoceria prepared
with a
combination of citric acid (CA) and EDTA, wherein the molar ratio of CA/EDTA
ranges from
3.0 to 0.1. Amelioration of disease progression and improvement in motor
behavior tests
resulted in murine models of chronic-progressive multiple sclerosis, relapse-
remitting
multiple sclerosis, amyotrophic lateral sclerosis and ischemic reperfusion
injury.
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 4 -
[0012] As described previously, various methods have been reported for
preparing
biocompatible dispersions of cerium-containing nanoparticles, and in
particular those .
stabilized with citric acid or citrate ion. However, a need remains for
further improvement
in the free radical scavenging ability of citric acid stabilized cerium-
containing nanoparticle
dispersions, used, for example, to treat the effects of oxidative stress
related diseases and
events, such as ischemic stroke.
SUMMARY OF THE INVENTION
[0013] In accordance with one aspect of the invention, a process of
making a dispersion
of nanoparticles is provided, comprising: forming a reaction mixture
comprising cerous ion,
citric acid, a stabilizer selected from the group consisting of
nitrilotriacetic acid, ethylene
glycol tetraacetic acid and diethylenetriaminepentaacetic acid, an oxidant,
and water;
optionally heating or cooling the reaction mixture, and thereby forming a
dispersion of
cerium-containing nanoparticles in the reaction mixture.
[0014] In a second aspect of the invention, a process of treating an
oxidative stress
related disease or event, such as ischemic stroke, comprising administering
before, during or
after onset of a disease or event, a cerium-containing nanoparticle prepared
in the presence
of a mixture of citric acid and a stabilizer selected from the group
consisting of
nitrilotriacetic acid, ethylene glycol tetraacetic acid and
diethylenetriaminepentaacetic acid,
is provided.
[0015] In a third aspect of the invention, a nanoparticle comprising
cerium, citric acid
and a stabilizer selected from the group consisting of nitrilotriacetic acid,
ethylene glycol
tetraacetic acid and diethylenetriaminepentaacetic acid, is provided.
DETAILED DESCRIPTION OF THE INVENTION
[0016] It is to be understood that elements not specifically shown or
described may take
various forms well known to those skilled in the art. The invention is defined
by the claims.
[0017] In this application, the term nanoparticle includes particles
having a mean
diameter of less than 100 run. For the purposes of this disclosure, unless
otherwise stated,
the diameter of a nanoparticle refers to its hydrodynamic diameter, which is
the diameter
determined by dynamic light scattering technique and includes molecular
adsorbates and the
accompanying solvation shell of the particle. Alternatively, the geometric
particle diameter
can be estimated by analysis of transmission electron micrographs (TEM).
[0018] In this application, various cerium-containing materials are
nominally described
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 5 -
as "cerium oxide" or "cerium dioxide." It is understood by one skilled in the
chemical arts,
that the actual oxidic anions present in these materials may comprise oxide
anions or
hydroxide anions, or mixtures thereof, such as hydrated oxide phases (e.g.
oxyhydroxide).
In addition, it is known that compositions of matter may be comprised of solid
solutions of
multivalent cations, and are termed non-stoichiometric solids. Thus, for oxide
phases
comprised of metal cations of multiple oxidation states, it is understood that
the total
amount of oxidic anions present in a bulk phase will be determined by the
specific amounts
of the various oxidation states of the metal cations present (e.g. Ce3+ and
Ce4), such that
charge neutrality is maintained. For non-stoichiometric phases nominally
described as
metal dioxides, this is embodied in the chemical formula M02_8, wherein the
value of 8
(delta) may vary. For cerium oxides, Ce02.8, the value of 8 (delta) typically
ranges from
about 0.0 to about 0.5, the former denoting cerium (IV) oxide, Ce02, the
latter denoting
cerium (III) oxide, Ce01.5 (alternatively denoted Ce203). Alternatively, the
value of 8
(delta) denotes the amount of oxygen vacancies present relative to cerium (IV)
oxide
(Ce02). For each oxygen di-anion vacancy present, two cerous ions (Ce3+) are
present, to
preserve charge neutrality.
[0019] In one aspect of the invention, a process of making a dispersion
of nanoparticles
is provided, comprising: forming a reaction mixture comprising cerous ion,
citric acid, a
stabilizer (chelator) selected from the group consisting of nitrilotriacetic
acid, ethylene
glycol tetraacetic acid and diethylenetriaminepentaacetic acid, an oxidant,
optionally
heating or cooling the reaction mixture, and thereby forming a dispersion of
cerium-
containing nanoparticles in the reaction mixture.
[00201 According to at least one embodiment, the molar ratio of citric
acid to the
stabilizer may range from about 0.1:0.9 to about 0.9:0.1, such as, for
example, from about
0.25:0.75 to about 035:0.25, or from about 0.4:0.6 to about 0.6:0.4. In at
least one
embodiment, the citric acid and stabilizer are present in a molar ratio of
about 0.5:0.5.
[00211 In one embodiment of the invention, a process of making a
dispersion of
nanoparticles is provided, comprising: forming a reaction mixture comprising
cerous ion,
citric acid, a stabilizer selected from the group consisting of
nitrilotriacetic acid, ethylene
glycol tetraacetic acid and diethylenetriaminepentaacetic acid, an oxidant,
and water;
optionally heating or cooling the reaction mixture, and directly forming,
without isolation of
the nanoparticles, a dispersion of cerium-containing nanoparticles in the
reaction mixture.
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 6 -
[0022] In various embodiments, the oxidant includes compounds more
oxidizing than
molecular oxygen (or an ambient atmosphere of air). In other embodiments, the
oxidant has
an aqueous half-cell reduction potential greater than -0.13 volts relative to
the standard
hydrogen electrode. In at least one embodiment the oxidant is an alkali metal
or ammonium
perchlorate, chlorate, hypochlorite or persulfate; ozone, a peroxide or a
combination thereof
In at least one embodiment, a two-electron oxidant, such as hydrogen peroxide,
is used. In
accordance with at least one embodiment, hydrogen peroxide is present in an
amount
greater than one-half the molar amount of cerous ion. In still other
embodiments, the
amount of oxidant present varies widely in relation to the amount of cerium
ions or other
metal ions present.
[0023] In at least one embodiment, molecular oxygen is passed through the
reaction
mixture.
[0024] In various embodiments, the temperature of the reaction mixture is
greater than
or less than ambient temperature. In at least one embodiment, the reaction
mixture is heated
or cooled to temperatures greater than 20 'V, or less than or equal to 20 C.
In various
embodiments, the reaction mixture is heated or cooled to temperatures greater
than about 30
C, about 40 C, about 50 C, about 60 C, about 70 C, about 80 C or about 90
C. In
another embodiment, the reaction mixture is heated or cooled to a temperature
less than or
equal to the boiling temperature of water.
[0025] In various embodiments, the nanoparticles formed arc amorphous, semi-
crystalline or crystalline. As used herein, the term "crystalline," unless
otherwise specified,
is used to describe nanoparticles having at least some crystalline structure,
i.e., either semi-
crystalline or crystalline. In at least one embodiment the nanoparticles
formed are
characterized by a cubic fluorite crystal structure. According to at least one
embodiment,
the nanoparticles formed are characterized by a cerium oxide crystal
structure.
[0026] In at least one embodiment, the crystallinity of the nanoparticles
formed is
enhanced by heating of the reaction mixture.
[0027] According to at least one embodiment, the nanoparticles formed are
dehydrated
or dehydroxylated by heating of the reaction mixture.
[0028] In various embodiments, the dispersion of cerium-containing
nanoparticles
contains substantially non-agglomerated nanoparticles, greater than 90 percent
non-
agglomerated nanoparticles, greater than 95 percent non-agglomerated
nanoparticles,
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 7 -
greater than 98 percent non-agglomerated nanoparticles, and entirely non-
agglomerated
nanoparticles.
[0029] In at least one embodiment, the non-agglomerated nanoparticles are
crystalline,
and are alternatively referred to as single particle crystallites or
individual crystallites.
[0030] In various embodiments, the nanoparticles formed have a hydrodynamic
diameter less than 100 nm, less than 20 nm, less than 10 min, less than 5.0
nm, less than 3.0
nm or less than about 2.0 nm, while having a hydrodynamic diameter greater
than about 1.0
nm.
[0031] In at least one embodiment, a nanoparticle comprising cerium is
provided. In
other embodiments, nanoparticles comprising a cerium oxide, a cerium hydroxide
or a
cerium oxyhydroxide are provided.
[0032] In accordance with at least one embodiment, a nanoparticle
comprising cerium,
citric acid and a stabilizer selected from the group consisting of
nitrilotriacetic acid,
ethylene glycol tetraacctic acid and diethylenetriaminepentaacetic acid, is
provided.
[0033] In various embodiments, the nanoparticle dispersion formed are
characterized by
a zeta potential ranging from about -30 mV to about +30 mV. In at least one
embodiment,
the zeta potential of the nanoparticle dispersion ranges from about -15 mV to
about -30 mV.
[0034] In other embodiments, the zeta potential of the nanoparticle is
altered by
adjusting the pH of the nanoparticle dispersion, by adjusting the type and
amount of
stabilizer (e.g. citric acid, nitrilotriacetic acid, ethylene glycol
tetraacetic acid or
diethylenetriaminepentaacetic acid) content to less than saturation coverage,
or both.
[0035] In at least one embodiment, the nanoparticle dispersion formed is
washed to
remove excess ions or by-product salts. In various embodiments, the
nanoparticle
dispersion is washed such that the ionic conductivity is reduced to less than
about 15
millisiemens per centimeter (mS/cm), less than about 10 mS/cm, less than about
5 mS/cm or
less than about 3 mS/cm. In various embodiments, the nanoparticle dispersion
formed is
washed by dialysis or diafiltration.
100361 According to at least one embodiment, the nanoparticle dispersions
formed are
concentrated to remove excess solvent or excess water. In various embodiments,
the
nanoparticle dispersion is concentrated by diafiltration or centrifugation.
[0037] In various embodiments, the concentration of nanoparticles in the
dispersion is
greater than about 0.05 molal, greater than about 0.5 molal or greater than
about 2.0 molal
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 8 -
(approximately 35% solids in a given dispersion).
[0038] In various embodiments, the size distributions of the
nanoparticles are
substantially monomodal. In other embodiments, the nanoparticle size has a
coefficient of
variation (COV) less than about 30%, less than about 25%, less than about 20%,
less than
about 15%, less than about 10% or less than about 5%, where the COV is defined
as the
standard deviation divided by the mean.
[0039] In various embodiments, the dispersion of cerium-containing
nanoparticles is
stable against particle agglomeration and settling, as demonstrated, for
example, by
maintenance of a clear liquid appearance, for greater than 3 months, greater
than 6 months,
greater than .9 months, greater than 12 months, and greater than 16 months.
[0040] In various embodiments, the reaction mixture is formed in a batch
reactor, a
continuous reactor or a colloid mill. In at least one embodiment, the
continuous reactor is a
continuous-stirred-tank reactor or a plug-flow reactor.
[0041] In at least one embodiment, mixers can be used to agitate and mix
the reactants.
In various embodiments, mixers comprising stir bars, marine blade propellers,
pitch blade
turbines or flat blade turbines are used. In at least one embodiment, a high
shear mixer that
forces the reaction mixture to pass through a screen, wherein holes vary in
size from
fractions of a millimeter to several millimeters, is employed.
[0042] Physiological pH is typically in the range of about 7.2 to about
7.4.
[0043] Without being bound by any theory, the proposed use of cerium oxides
for the
treatment of inflammation and oxidative stress related diseases (e.g. ROS
mediated
diseases) is based in part upon a belief that cerium oxides may function as
catalytic
scavengers of free radicals. The existence of and facile inter-conversion of
cerium in a
mixture of Ce3 and Ce4+ valence states may enable cerium oxides to reduce
and/or oxidize
free radicals to less harmful species in a catalytic or auto-regenerative
manner. Redox
reactions may occur on the surface of cerium oxide nanoparticles (CeNPs) that
neutralize
tissue-damaging free radicals. For example, it is believed to be desirable to
oxidize
superoxide anion (02-) to molecular oxygen, to oxidize peroxynitrite anion
(0N00-) to
physiologically benign species, and to reduce hydroxyl radical (.0H) to
hydroxide anion.
This may in turn enable a greatly reduced dosing regimen in comparison to, for
example,
sacrificial antioxidants currently available to treat oxidative stress related
diseases and
events.
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 9 -
[0044] In at least one embodiment, administered nanoceria particles of
the invention are
taken into cells through cell membranes and reside in the cellular cytoplasm
or in various
cellular organelles, such as the nucleus and mitochondria. In other
embodiments, the
nanoccria particles of the invention reside in intravascular or interstitial
spaces, wherein
they may reduce oxidative stress and inflammation by eliminating free radicals
or reducing
autoimmune responses. In at least one embodiment, the immune system invasion
of the
central nervous system resulting from breakdown of the blood-brain barrier
(BBB) or
blood-cerebrospinal fluid barrier (BCFB) or blood-ocular barrier (BOB) is
modulated by
nanoceria particles of the invention.
[0045] In another embodiment, the nanoceria particles of the invention are
particles
capable of crossing a mammalian blood brain barrier. In various embodiments,
nanoceria
particles of the invention cross a mammalian blood brain barrier and reside in
brain
parenchyma tissues as aggregates or agglomerates of a size less than about 100
nm, less
than about 50 nm, less than about 20 nm, less than about 10 nm, less than
about 5 nm. In at
least one embodiment, nanoceria particles of the invention cross a mammalian
blood brain
barrier and reside in brain parenchyma tissues as independent, non-
agglomerated
nanoparticles of a size less than about 3.5 run.
[0046] In at least one embodiment, a pharmaceutical composition
comprising nanoceria
particles of the invention are specifically contemplated for prevention and/or
treatment of
oxidative stress related diseases and events, such as, but not limited to,
Alzheimer's Disease,
Parkinson's Disease, Huntington's Disease, amyotrophic lateral sclerosis
(ALS), ataxia,
Friedreich's ataxia, autism, obsessive-compulsive disorder, attention deficit
hyperactivity
disorder, migraine, stroke, traumatic brain injury, cancer, inflammation,
autoimmune
disorders, lupus, multiple sclerosis (MS), inflammatory bowel disease, Crohn's
Disease,
ulcerative colitis, stenosis, restenosis, atherosclerosis, metabolic syndrome,
endothelial
dysfunction, vasospasms, diabetes, aging, chronic fatigue, coronary heart
disease, cardiac
fibrosis, myocardial infarction, hypertension, angina, Prizmetal's angina,
ischemia,
angioplasty, hypoxia, Keshan disease, glucose-6-phosphate dehydrogenase
deficiency,
favism, ischemic reperfusion injury, rheumatoid and osteo-arthritis, asthma,
chronic
obstructive pulmonary disease (e.g. emphysema and bronchitis), allergies,
acute respiratory
distress syndrome, chronic kidney disease, renal graft, nephritis, ionizing
radiation damage,
sunburn, dermatitis, melanoma, psoriasis, macular degeneration, retinal
degeneration,
CA 02910212 2015-10-22
WO 2014/176487 PCT/1JS2014/035434
- 10 -
cataractogenesis, among others.
[0047] In accordance with various embodiments, a pharmaceutical
composition
comprising nanoceria particles of the invention are specifically contemplated
for prevention
and/or treatment of oxidative stress related cellular pathologies, such as,
but not limited to,
mitochondrial dysfunction, lysosome and proteasome dysfunction, oxidation of
nucleic
acids (e.g. RNA and DNA), tyrosine nitration, loss of phosphorylation mediated
signaling
cascades, initiation of apoptosis, lipid peroxidation and destruction of the
membrane lipid
environment.
[0048] In various embodiments, a pharmaceutical composition comprising
nanoceria
particles of the invention is administered to a human or a non-human subject,
such as
another mammal, including, but not limited to, a canine, a feline, a bovine,
an equine, an
ovine, a porcine or a rodent. Alternatively, the subject of administration can
be an animal
such as a bird, insect, reptile, amphibian, or any companion or agricultural
animal.
[0049] In various embodiments, nanoceria particles of the invention are
administered in
vivo to a subject by topical, enteral or parenteral methods, including
injections, infusions or
implantations. More particularly, it is specifically contemplated to
administer nanoceria
particles of the invention by any of the following routes: auricular (otic),
buccal,
conjunctival, cutaneous, dental, eleetro-osmosis, endocervical, endosinusial,
endotracheal,
enteral, epidural, extra-amniotic, extracorporeal, hcmodialysis, infiltration,
interstitial, intra-
abdominal, intra-amniotic, intra-arterial, intrabiliary, intrabronchial,
intrabursal,
intracardiac, intracartilaginous, intracaudal, intracavernous, intracavitary,
intracerebral,
intracisternal, intracorneal, intracornal-dental, intracoronary, intracorporus
cavernosum,
intradermal, intradiscal, intraductal, intraduodenal, intradural,
intraepidermal,
intraesophageal, intragastric, intragingival, intraileal, intralesional,
intraluminal,
intralyrnphatic, intramedullary, intrameningeal, intramuscular, intraocular,
intraovarian,
intrapericardial, intraperitoneal, intrapleural, intraprostatic,
intrapulmonary, intrasinal,
intraspinal, intrasynovial, intratendinous, intratesticular, intrathecal,
intrathoracic,
intratubular, intratumor, intratympanic, intrauterine, intravascular,
intravenous, intravenous
bolus, intravenous drip, intraventricular, intravesical, intravitreal,
iontophoresis, irrigation,
laryngeal, nasal, nasogastric, occlusive dressing technique, ophthalmic, oral,
oropharyngeal,
parenteral, percutaneous, periarticular, peridural, perineural, periodontal,
rectal, respiratory
(inhalation), retrobulbar, soft tissue, subarachnoid, subconjunctival,
subcutaneous,
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 11 -
sublingual, submucosal, topical, transdermal, transmammary, transmucosal,
transplacenta,
transtracheal, transtympanic, ureteral, urethral, vaginal, and any other or
unassigned route.
[0050] In other embodiments, nanoceria particles of the invention are
retained in or on
the surface of a medical device or prosthesis, such as a cannula, catheter or
stent, thereby
reducing inflammation locally or systemically, over either a short or long
time period.
[0051] In various embodiments, the nanoceria particles of the invention
are delivered in
any suitable form known in the art, including, but not limited to, a
suspension, gel, tablet,
enteric coated tablet, loaded liposome, powder, suppository, infusible,
lozenge, cream,
lotion, salve, or inhalant.
[0052] In various embodiments, the nanoceria particles of the invention are
combined
with other pharmaceutically acceptable substances, such as, but not limited
to, water, salts,
buffers, phosphate buffered saline (PBS), sugars, human or bovine serum
albumen, lipids,
drugs, colorants, flavorants, binders, gums, surfactants, fillers or any
excipients known in
the art.
[0053] In at least one embodiment, the vehicle comprising the nanoceria
particles of the
invention is sterilized prior to administration.
[0054] In other embodiments, a cell or cell culture is contacted with a
nanoceria particle
or particles of the invention. Contact may be practiced by exposing a cell or
cell culture by
in vitro or ex vivo methods, wherein the latter method comprises re-
introducing the treated
cell or cells into a subject, such as the subject from which the cell or cells
were originally
obtained. In various embodiments the cell is prokaryotic or eukaryotic in
nature. In at least
one embodiment, the treated cells are used in the production of proteins used
in the
pharmaceutical industry, generally known as biologics, such as, but not
limited to, antigens,
antibodies and vaccines. In another embodiment, the treated cells are used in
a fermentation
process.
[0055] The invention is further illustrated by the following examples,
which are not
intended to limit the invention in any manner.
EXPERIMENTAL SECTION
Nanoparticle Scattering and Size Assessments
[0056] A simple qualitative characterization of the particle dispersions
was performed
by assessing the degree of Tyndell scattering exhibited by the dispersions
when illuminated
by a red laser pen light, relative to the amount of scattering from a sample
of the neat
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 12 -
solvent. A quantitative assessment of the particle size of the nanoparticle
dispersions was
performed by dynamic light scattering (DLS) using a Brookhaven 90Plus Particle
Size
Analyzer (Brookhaven Instruments Corp., Holtzville, New York, U.S.A.) equipped
with a
quartz cuvette. Reported DLS sizes are the lognormal number weighted
parameter.
Nanoparticle Charge Assessment
[0057] A quantitative assessment of the nanoparticle charge was made by
measuring the
zeta potential using a Zetasizer Nano ZS from Malvern Instruments.
Example 1: Preparation of Nanoparticles with Cerium and Citric Acid
[0058] Into a 800m1 glass beaker containing a magnetic stir bar was
introduced 500 ml
of high purity (HP) water. The water was then heated to about 70 C, and
therein 4.83
grams of citric acid (CA) were dissolved. Ammonium hydroxide (28-30 %) was
added to
adjust the pH of the solution to about 8.5. The temperature of the reaction
vessel was raised
to about 80 C. A 10.0 gm quantity of Ce(NO3)3'6(H20) was dissolved in 30 ml
of HP
water, and this solution was added slowly to the stirred reaction mixture over
several
minutes. In this way, equimolar amounts of CA and Ce had been added to the
reaction
mixture. Then a 50 ml solution containing 4.8 ml of 50% H202(3.0 molar ratio
of H202 to
cerium) was added slowly over several minutes to the equimolar reaction
mixture of cerous
ion and citric acid. The reaction product was covered and then heated for an
additional
hour, resulting in a clear yellow suspension. After cooling with stirring, the
directly formed
nanoparticle dispersion was washed by diafiltration to an ionic conductivity
of less than
about 10 mS/cm, to remove excess salts.
[0059] The final product dispersion was a clear yellow liquid that
displayed a high
degree of Tyndall scattering when illuminated with a low intensity LASER beam,
indicating
it contained well-dispersed colloidal particles. Particle size analysis by
dynamic light
scattering indicated an average hydrodynamic diameter of 7.8 nm. Analysis of a
X-ray
diffraction (XRD) spectrum indicated the presence of a major crystalline phase
iso-
structural with Ce02 (PDF 4 34-394, eerianite) characterized by a cubic
fluorite structure.
An average crystallite size of 2.0 nm was determined by analysis of the (220)
peak width
using the Scherrer method.
Example 2: Preparation of Nanoparticles with Cerium, Citric Acid and DCTA
[0060] Into a 600m1 glass beaker containing a magnetic stir bar was
introduced 500 ml
of high purity (HP) water. A 2.41 gm quantity of citric acid (CA) was added to
the reaction
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 13 -
mixture. A 4.264 gm quantity of 1,2-Diaminocyclohexanetetraacetic acid
monohydrate
(DCTA) was dissolved in water along with about 6 ml of ammonium hydroxide to
aid in
dissolution, and added to the reaction mixture. Ammonium hydroxide (28-30 %)
was added
to adjust the pII of the solution to about 8.5. A 10.0 gm quantity of
Ce(NO3)3'6(H20) was
added. The molar proportions of CAJDCTA/Ce were 0.5/0.5/1Ø Then a 10 ml
solution
containing 4.8 gm of 50% H202(3.0 molar ratio of H202 to cerium ion) was added
slowly to
the cerium, citric acid and DCTA solution mixture. The reaction product was
then heated at
80 C for 1 hour. After cooling with stirring, the directly formed
nanoparticle dispersion
was washed by diafiltration to an ionic conductivity of less than about 10
mS/cm, to remove
excess salts.
[0061] After cooling, the final product dispersion was a clear light
orange colored liquid
that displayed a high degree of Tyndall scattering when illuminated with a low
intensity
LASER beam, indicating it contained well-dispersed colloidal particles.
Particle size
analysis by dynamic light scattering indicated a hydrodynamic diameter of 2.6
nm with a
polydispersity of 0.227. Analysis of a X-ray diffraction (XRD) spectrum
indicated the
presence of a major crystalline phase iso-structural with Ce02 (PDF # 34-394,
cerianite)
characterized by a cubic fluorite structure. An average crystallite size of
1.9 nm was
determined by analysis of the (220) peak width using the Scherrer method.
Example 3: Preparation of Nanopartieles with Cerium, Citric Acid and NTA
[0062] Into a 600m1 glass beaker containing a magnetic stir bar was
introduced 500 ml
of high purity (HP) water. A 2.41 gm quantity of citric acid (CA) was added to
the reaction
mixture. A 3.129 gm quantity of 2,2',2"-Nitrilotriacetic acid (NTA, CAS No.
139-13-9)
was dissolved in water along with ammonium hydroxide to aid in dissolution,
and added to
the reaction mixture. Ammonium hydroxide (28-30 %) was added to adjust the pH
of the
solution to about 8.5. A 10.0 gm quantity of Ce(NO3)3'6(H20) was added. The
molar
proportions of CA/NTA/Ce were 0.5/0.5/1Ø Then a 10 ml solution containing
4.8 gm of
50% H202(3.0 molar ratio of H202 to cerium ion) was added slowly to the
cerium, citric
acid and NTA solution mixture. The reaction product was then heated at 80 C
for 1 hour.
After cooling with stirring, the directly formed nanoparticle dispersion was
washed by
diafiltration to an ionic conductivity of less than about 10 mS/cm, to remove
excess salts.
[0063] The final product dispersion was a clear yellow liquid that
displayed a high
degree of Tyndall scattering when illuminated with a low intensity LASER beam,
indicating
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 14 -
it contained well-dispersed colloidal particles. Particle size analysis by
dynamic light
scattering indicated a hydrodynamic diameter of 2.8 nm with a polydispersity
of 0.264.
Example 4: Preparation of Nanoparticles with Cerium, Citric Acid and EGTA
[0064] Into a 600m1 glass beaker containing a magnetic stir bar was
introduced 500 ml
of high purity (HP) water. A 2.41 gm quantity of citric acid (CA) was added to
the reaction
mixture, A 4.497 gm quantity of Ethylene Glycol Tetraacetic acid (EGTA, CAS
No. 67-42-
5) was dissolved in water along with ammonium hydroxide to aid in dissolution,
and added
to the reaction mixture. Ammonium hydroxide (28-30 %) was added to adjust the
pH of the
solution to about 8.5. A 10.0 gm quantity of Ce(NO3)3'6(H20) was added. The
molar
proportions of CA/EGTA/Ce were 0.5/0.5/1Ø Then a 10 ml solution containing
4.8 gm of
50% H202(3.0 molar ratio of H202 to cerium ion) was added slowly to the
cerium, citric
acid and EGTA solution mixture. The reaction product was then heated at 70 C
for 1 hour.
After cooling with stirring, the directly formed nanoparticle dispersion was
washed by
diafiltration to an ionic conductivity of less than about 10 mS/cm, to remove
excess salts.
[0065] The final product dispersion was a clear orange liquid that
displayed a high
degree of Tyndall scattering when illuminated with a low intensity LASER beam,
indicating
it contained well-dispersed colloidal particles. Particle size analysis by
dynamic light
scattering indicated a hydrodynamic diameter of 8.5 nm with a polydispersity
of 0.393.
Example 5: Preparation of Nanoparticles with Cerium, Citric Acid and DTPA
[0066] Into a 600m1 glass beaker containing a magnetic stir bar was
introduced 500 ml
of high purity (HP) water. A 2.89 gm quantity of citric acid (CA) was added to
the reaction
mixture. A 3.606 gm quantity of Diethylenetriaminepentaaeetie acid (DTPA, CAS
No. 67-
43-6) was added to the reaction mixture. Ammonium hydroxide (28-30 %) was
added to
adjust the p1-1 of the solution to about 8.5. A 10.0 gm quantity of
Ce(NO3)3'6(H20) was
added. The molar proportions of CA/DTPA/Ce were 0.6/0.4/1Ø Then a 10 ml
solution
containing 4.8 gm of 50% H202(3.0 molar ratio of H202 to cerium ion) was added
slowly to
the cerium, citric acid and DTPA solution mixture. The reaction product was
then heated at
80 C for 1 hour. After cooling with stirring, the directly formed
nanopartiele dispersion
was washed by diafiltration to an ionic conductivity of less than about 10
mS/cm, to remove
excess salts.
[0067] The final product dispersion was a clear red liquid that displayed
a high degree
of Tyndall scattering when illuminated with a low intensity LASER beam,
indicating it
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 15 -
contained well-dispersed colloidal particles. Particle size analysis by
dynamic light
scattering indicated a hydrodynamic diameter of 2.4 nm with a polydispersity
of 0.212.
Analysis of a X-ray diffraction (XRD) spectrum indicated the presence of a
major
crystalline phase iso-structural with Ce02 (PDF # 34-394, cerianite)
characterized by a
= 5 cubic fluorite structure. An average crystallite size of 2.1 nm was
determined by analysis of
the (220) peak width using the Scherrer method.
[0068] A sample of the final product dispersion was stored in the dark
at ambient
temperature and pressure for a time period greater than 16 months with no
change in the
clarity of the liquid and no change in particle hydrodynamic diameter and
polydispersity.
Evaluation of Stabilized Nanoceria in a Murinc Model of Ischemic Stroke
[0069] The ability of cerium-containing nanoparticles (e.g. nanoceria)
to reduce
oxidative stress was evaluated in a modification of the in vitro mouse
hippocampal brain
slice model of ischemia described by Estevez, AY; etal., Neuroprotective
mechanisms of
cerium oxide nanoparticles in a mouse hippocampal brain slice model of
ischemia, Free
Radic. Biol. Med. (2011)51(6):1155-63 (doi:10.1016/j .radbiomed.2011.06.006).
[0070] Adult (2-5 months of age) CD1 mice were sacrificed via rapid
decapitation and
their brains quickly removed and placed in a chilled choline-based slicing
solution
containing 24 mM choline bicarbonate, 135 mM choline chloride, 1 mM kynurenic
acid, 0.5
mM CaCl2, 1.4 mM Na2PO4, 10 mM glucose, 1 mM KC1, and 20 mM MgCl2 (315 mOsm).
Transverse hippocampal slices, 400 m thick, were cut along a rostral-to-
caudal axis (-1.2
to -2.8 mm Bregma) using a Leica VT1200 Vibratome (Leica Microsystems,
Wetzlar,
Germany) and allowed to recover for 1 hr in a control artificial cerebral
spinal fluid (aCSF)
containing 124 mM NaCl, 3 mM KC1, 2.4 mM CaCl2, 1.3 mM MgSO4, 1.24 mM K3PO4,
26
mM NaHCO3, 10 mM glucose and bubbled with 5% CO2, 95% 02 gas (pH 7.4, 300
mOsm). Hippocampal slices were placed in a culture dish and stored in a NuAire
humidified incubator (NuAire, Plymouth, MN, USA) at 37 C with 5% CO2 for up
to 48 hr.
[0071] Oxidative stress from ischemia was induced by placing the brain
slices in
hypoglycemic, acidic and hypoxic aCSF (glucose and pH were lowered to 2 mM and
6.8,
respectively, and the solution was bubbled with 84% N2, 15% CO2, and 1% 02) at
37 C for
30 min. Sucrose was added to maintain the osmolarity of the solution at about
295 mOsm.
[0072] Aqueous dispersions of cerium-containing nanoparticles prepared
as described in
Examples 1-5 supra were administered in matched doseage in a delivery volume
of 1 lig per
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 16-
1 ml aCSF or medium (equivalent to 5.8 uM) at the onset of the ischemic event,
and
remained in the medium throughout the remainder of the experiment. Control
slices
received an equal volume of vehicle control. Various delivery vehicles were
used with
similar success for the cerium oxide nanoparticles prepared as described
herein, including
distilled water alone, saline solution, Na-citrate solution, PBS, and
combinations thereof.
[0073] After exposure to 30 minutes of oxidative stress (ischemic
conditions), the living
brain slices (test and control) were incubated for 24 hr in organotypic
culture by placing
them in a 35 mm culture dish containing culture medium and Millipore inserts
(Millipore,
Billerica, MA, USA). Culture medium contained 50% minimum essential medium
(Hyclone Scientific, Logan UT, USA), 25% horse serum, 25% Hank's balanced salt
solution
(supplemented with 28 mM glucose, 20 mM HEPES and 4 mM NaHCO3), 50 U/ml
penicillin, and 50 p1/ml streptomycin, pH 7.2.
[0074] The extent of cell death was measured 24 hours after the oxidative
injury using
fluorescence imaging techniques. Each set of brain slices studied in the test
condition (i.e.
administered with cerium-containing nanoparticles) was matched with a similar
set of
control brain slices treated identically in every way except for
administration of vehicle
alone. Thus on each study day, two sets of anatomically matched brain slices
taken from
age-matched and sex-matched littermates were subjected to either the test
condition
(administered with cerium-containing nanoparticles) or control (vehicle
alone). During
fluorescence imaging measurements, the light intensity, duration of image
capture, and
timing of image collection were identical for the test condition and vehicle
control brain
slices. Results were expressed as the ratio of the fluorescence in the test
condition to the
fluorescence in the matched control slice imaged at the same time point in the
experimental
sequence.
[0075] At 24 hours post oxidative injury, paired (control and test) brain
slices were
incubated for 20 min in culture medium containing 0.81 !AM vital exclusion dye
SYTOX
Green (Invitrogen, Carlbad, CA, USA) and, subsequently, washed for 15-20 min
in culture
medium to remove unincorporated dye. SYTOX Green is a fluorescent dye that
binds to
DNA and RNA. However, it is excluded from the cell nucleus by the cell
membrane in
intact, viable cells. Therefore, it acts as a vital dye and stains only those
dead and dying
cells in which the cell membrane has become permeable so that the dye has
access to the
cell interior. After staining and washing, brain slices were transferred to
the stage of a
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 17 -
Nikon TE 2000-U (Nikon Instruments, Melville, NY, USA) microscope equipped
with
epifluoresence attachments and a 150-W xenon light source (Optiquip, Highland
Mills, NY,
USA). Control aCSF solution was loaded into 60-ml syringes, equilibrated with
95%
02/5% CO2, and heated to 37 'V using a servo-controlled syringe heater block,
stage heater,
and in-line perfusion heater (Warner Instruments, Hamden, CT, USA). The brain
sections
were continuously perfused with warmed, 95% 02/5% CO2 equilibrated aCSF at a
rate of 1
ml per minute. After 5 min, images of the hippocampal formation of each
control and test
brain slice were collected using a 4x Plan Flour objective (Nikon Instruments)
under
identical conditions (i.e. light intensity, exposure time, camera acquisition
parameters).
SYTOX Green fluorescence was measured by briefly (620 ms) exciting the tissue
at 480
40 nm, filtering the emitted fluorescence (535 50 nm) from the probe using a
505 nm,
long-pass, dichroic mirror (Chroma technology, Bennington, VT, USA),
intensifying, and
measuring with a cooled CCD gain EM camera (Hamamatsu CCD EM C9100;
Bridgewater,
NJ, USA). The digital images were acquired and processed with Compix SimplePCI
6.5
software (C Imaging Systems, Cranberry Township, PA, USA).
[0076] The light intensity resulting from the SYTOX Green loading
reflected the
number of dead or dying cells within the calculated area. The light-intensity
measurements
were performed automatically using the Compix SimplePCI 6.5 software, thereby
eliminating experimenter bias in selecting the regions of interest.
[0077] Reduction in cell death is reported as the ratio of the light
intensity of SYTOX
Green fluorescence from the cornu ammonis fields (oriens layer, stratum
radiatum and
lacunosum moleculare) for the test condition (i.e. nanoceria treated) to the
control
(untreated) for anatomically matched hippocampal sections taken from age-
matched and
sex-matched littermate brains sliced and exposed to ischemic oxidative stress
on the same
day, and fluorescence imaged 24 hr after the ischemic insult.
[0078] Cerium-containing nanoparticles prepared with citric acid
stabilizer alone, and
with a mixture of biocompatible stabilizers comprising citric acid and one of
DCTA, NTA,
EGTA or DTPA, prepared as described in Example 1-5, were evaluated in the
mouse
hippocampal brain slice model of ischemic stroke using a treatment
concentration of 5.8
1.tM. Results for the reduction in cell death (percent reduction relative to
control),
commonly referred to as sparing, as a function of nanoparticle stabilizer are
given in Table 1
below.
CA 02910212 2015-10-22
WO 2014/176487 PCT/US2014/035434
- 18 -
'fable 1
Source of DLS
Stabilizer(s) Sparing Comment
Nanoparticles (nm)
Ex. 1 CA 7.8 15.5% Comparative
Ex. 2 CA/ DCTA 2.6 14.2% Comparative
Ex. 3 CA/NTA 2.8 17.0% Inventive
Ex. 4 CA/EGTA 8.5 23.3% Inventive
Ex.5 CA/DTPA 2.4 34.0% Inventive
[0079] Results shown in Table 1 above indicate that an improvement in
sparing (i.e. a
greater reduction in cell death) occurred when the cerium-containing
nanoparticles were
prepared with a combination of citric acid (CA) and either NTA, EGTA or DTPA.
[0080] While the invention has been described by reference to various
specific
embodiments, it should be understood that numerous changes may be made within
the spirit
and scope of the inventive concepts described. Accordingly, it is intended
that the invention
not be limited to the described embodiments, but will have full scope defined
by the claims.
